Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

HEM Pharma secures $40.4M in convertible bonds led by GVA Asset Management to support construction of Sejong Plant 2 and growth in the global market.

PRIVATEAug 20, 2026•about 3 hours ago

Amount Raised

$40.4 Million

Round Type

Convertible Note

BiotechnologyHealth Care

Investors

A1 Asset ManagementKorea Investment & SecuritiesTimefolio Asset ManagementKorean Growth FundGva Asset Management

Description

HEM Pharma has completed its second convertible bond issuance totaling 54 billion won ($40.4 million) led by GVA Asset Management. The funding will aid in expanding their production with Sejong Plant 2 to meet rising global demand. Institutional investors' participation underscores confidence in HEM Pharma's growth. The company is targeting commercial operation in the second half of 2027.

Company Information

Company

HEM Pharma

About

HEM Pharma is a microbiome healthcare company focused on innovative probiotic products and microbiome analysis services. The company is expanding its operations to meet increasing global demand for personalized probiotics. HEM Pharma has successfully secured orders and is constructing a new plant to enhance production capabilities. It aims to enter major markets like the U.S. and Japan by 2027.

Don't miss HEM Pharma's next move

Get an email the moment HEM Pharma raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for HEM Pharma's next move

Learn about Strategic plan

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

HEM Pharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.